COVID-19 halts the Trauma Market’s Q120 growth, leading to a -2.8% YoY decline globally.

Q120 was tracking as a stable quarter for the US Trauma Market, following Q419’s +3.8% growth, however, this was interrupted in mid-March by the COVID-19 pandemic. The US Trauma Market was down -1.2% YoY for the quarter, with WW revenues declining -2.8%. The non-elective trauma market experienced a reduction in trauma admissions due to the decrease in daily activities and limited driving for most of the US.

Among the many topics covered in the comprehensive Q120 Trauma Market Recap* are:

Tough comps and pricing pressure dampen growth during Q419

According to BioMedGPS’ SmartTRAK Financial Dashboard, the WW Trauma Market posted +2.8% growth, down from Q3, while the US achieved growth of +3.8%, also down from Q3. Trauma market leader DePuy Synthes (48.6% US Q4 share) reported while sales were down compared to Q319, gains were driven by overall market growth and strong adoption of their Femoral Neck System.

Tough comparisons, both YoY and sequentially, impacted the Q419 Trauma Market. The US pricing environment remains relatively steady as DePuy Synthes noted pricing pressure of -2.0%, in line with their Q2 and Q3 pricing (Q1 was -2.5%). Zimmer Biomet’s SET pricing improved in Q4 at -1.8% vs. Q3’s -2.0%. BioMedGPS believes 2019 pricing trended at -2.0 to -2.5%.

Among the many topics covered in the comprehensive Q419/FY19 Trauma Market Recap* are:

Easy YoY comps along with new product introductions help drive sequential growth 

SmartTRAK reports that In Q319, the WW Trauma Market (defined as fixation of the pelvis, femur & proximal/shaft portion of the tibia) increased +3.7% (as reported), with the US posting +4.6% growth. Q319 WW share leaders remained relatively steady compared to last year, with top trauma player DePuy Synthes, followed by Stryker, Zimmer Biomet and Smith & Nephew. The WW Trauma Market Segment shares were...

Among the many topics covered in the complete, comprehensive  Q319 Trauma Market Recap*  are:

New products help drive sequential improvement in growth 

The WW Market for Foot & Ankle Fixation exceeded $, up +3.9%, as reported, during Q319, up sequentially due to easy YoY comps. The US Foot & Ankle Fixation market also experienced a sequential increase, resulting in +4.3% reported growth. Major players reported improved growth while smaller players announced new product introductions throughout the quarter.

Stryker posted accelerated trauma & extremities growth in Q319,
reaching $, up +9.3% in the foot & ankle fixation segment according to SmartTRAK Financial Dashboard. The foot & ankle powerhouse reported US growth was positively impacted by double-digit growth across foot, ankle and shoulder products along with the T2 Alpha Nails. Stryker recouped lost share from Q2, gaining ~4.4% share to close Q3 at 25.6%. This gain allowed Stryker to take over the number one position from...

Among the many topics covered in the complete, comprehensive Q319 Extremities Market Recap* are:

SmartTRAK Interviews Carl Hasselman, MD about Arthrosurface’s alternative to toe fusions

Arthrosurface showcased its new BOSS Toe Fixation System at the American Orthopaedic Foot & Ankle Society’s (AOFAS 2019) Annual Meeting held September 11–15 in Chicago, IL. Recently 510k cleared, the system improves stabilization in a first metatarsal with a distal bone void. The Boss Toe Screw fills the current product gap in implant solutions for failed synthetic implants. The system provides an option for patients who want to avoid a toe fusion while regaining motion and enjoying an active lifestyle.

To find out more about the new BOSS Toe Fixation System, its benefits, and how it fits in Arthrosurface’s existing line of HemiCAP DF implants and ToeMotion Systems, SmartTRAK interviewed Carl Hasselman, MD, University of Pittsburgh Medical Center, at AOFAS 2019.

To listen to SmartTRAK’s interview with Dr. Hasselman, click on the following video (11:14 minutes). A transcript of the interview is also provided below.

Trauma segment experiences slight sequential gains as product intros gain traction and companies overcome supply disruption.

The WW Trauma Market ended Q2 posting +1.5% (reported) growth, with the US Market driving growth up 3.6% YOY, slightly up sequentially compared to Q1’s 3.2% gains. Internationally, Europe and ROW fared worse due to missed tenders, with -2.1% and -1.1% growth, respectively. Looking forward, SmartTRAK anticipates the trauma segment will see...

Among the many topics covered in the complete Q219 Trauma Market Recap* are:

Sequential improvement despite tough comps, supply disruption and pricing pressure

Tough comps, supply disruption and the ever-present pricing pressure impacts growth

SmartTRAK reports that the WW Trauma Market experienced a downturn in Q3, posting only +1.1% (reported) growth. The US Market was up +2.0% YoY, but is down sequentially compared to last quarter’s +5.0% gains...

Among the many topics covered in SmartTRAK's Q318 Trauma Market Recap are:

US market experiences slight softening as the top four trauma players all post sequential declines in Q218

The WW Trauma Market was up in Q218 – the third consecutive quarter of growth in the +4% range. Internationally, positive sales growth in Europe offset a sequential slowdown in Rest of World (ROW). In Europe, revenues were steady, while ROW sales dipped sequentially as the top players reported softer growth due to tough comps as a result of 2017 tender orders...

Among the many topics covered Q218 Trauma Market Recap are: